Breaking News, Collaborations & Alliances

Jubilant, Mnemosyne in Drug Discovery Pact

Will identify preclinical candidates for neuropsychiatric diseases

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Jubilant Biosys and Mnemosyne Pharmaceutical have entered a drug discovery collaboration to identify preclinical candidates for neuropsychiatric diseases from Mnemosyne’s subunit selective NMDA receptor modulators (SNRMs).   Mnemosyne will apply its NMDA receptor pharmacology expertise, supported by Jubilant’s translational center in Malvern, PA and facilities based in India. The collaboration will leverage capabilities across medicinal chemistry, NMDA receptor pharmacology, electrophysiol...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters